Concepedia

Author

Nong Xu

First Affiliated Hospital Zhejiang UniversityORCID

Also Known As

N. Xu, NONG XU, Nanjuan Xu, Ning-jie XU, Ningyuan Xu, Nong XU, Nong Xu, Xu, Nong, Yi Ba, Ying Wang

184

Publications

7.4K

Citations

30

H-Index

60

Concepts

All Affiliations

First Affiliated Hospital Zhejiang UniversityPeking UniversityPeking University Cancer HospitalSun Yat-sen UniversityThird Affiliated Hospital of Harbin Medical University
NX

About

Nong Xu is an author at First Affiliated Hospital Zhejiang University specializing in medicine, oncology, and cancer therapeutics.

Top Concepts

#ConceptH-IndexPublicationsCitations

1

Medicine

17

22

2K

2

Health Sciences

8

8

1.1K

3

Engineering

2

2

52

4

Natural Sciences

1

1

11

5

Biology

1

1

11

Nong Xu

×

57

Publications

6.1K

Citations

27

H-Index

YearCitations

Randomized, Double-Blind, Placebo-Controlled Phase III Trial of Apatinib in Patients With Chemotherapy-Refractory Advanced or Metastatic Adenocarcinoma of the Stomach or Gastroesophageal Junction

Jin Li, Shukui Qin, Jianming Xu,

Journal of Clinical Oncology

2016

976

Camrelizumab versus investigator's choice of chemotherapy as second-line therapy for advanced or metastatic oesophageal squamous cell carcinoma (ESCORT): a multicentre, randomised, open-label, phase 3 study

Jing Huang, Jianming Xu, Yun Chen,

The Lancet Oncology

2020

568

Apatinib for Chemotherapy-Refractory Advanced Metastatic Gastric Cancer: Results From a Randomized, Placebo-Controlled, Parallel-Arm, Phase II Trial

Jin Li, Shukui Qin, Jianming Xu,

Journal of Clinical Oncology

2013

548

Icotinib versus gefitinib in previously treated advanced non-small-cell lung cancer (ICOGEN): a randomised, double-blind phase 3 non-inferiority trial

Yuankai Shi, Li Zhang, Xiaoqing Liu,

The Lancet Oncology

2013

420

Effect of Fruquintinib vs Placebo on Overall Survival in Patients With Previously Treated Metastatic Colorectal Cancer

Jin Li, Shukui Qin, Rui‐Hua Xu,

JAMA

2018

378

Efficacy, Safety, and Correlative Biomarkers of Toripalimab in Previously Treated Recurrent or Metastatic Nasopharyngeal Carcinoma: A Phase II Clinical Trial (POLARIS-02)

Feng‐Hua Wang, Xiaoli Wei, Jifeng Feng,

Journal of Clinical Oncology

2021

336

Olaparib in combination with paclitaxel in patients with advanced gastric cancer who have progressed following first-line therapy (GOLD): a double-blind, randomised, placebo-controlled, phase 3 trial

Yung‐Jue Bang, Rui‐Hua Xu, Keisho Chìn,

The Lancet Oncology

2017

286

Efficacy and Tolerability of First-Line Cetuximab Plus Leucovorin, Fluorouracil, and Oxaliplatin (FOLFOX-4) Versus FOLFOX-4 in Patients With <i>RAS</i> Wild-Type Metastatic Colorectal Cancer: The Open-Label, Randomized, Phase III TAILOR Trial

Shukui Qin, Jin Li, Liwei Wang,

Journal of Clinical Oncology

2018

252

Surufatinib in advanced extrapancreatic neuroendocrine tumours (SANET-ep): a randomised, double-blind, placebo-controlled, phase 3 study

Jianming Xu, Lin Shen, Zhiwei Zhou,

The Lancet Oncology

2020

182

Efficacy and safety of a novel anti‐HER2 therapeutic antibody RC48 in patients with HER2‐overexpressing, locally advanced or metastatic gastric or gastroesophageal junction cancer: a single‐arm phase II study

Zhi Peng, Tianshu Liu, Jia Wei,

Cancer Communications

2021

182

Page 1